Home › Funds › T. Rowe Price Investment Management, Inc. › PCVX

T. Rowe Price Investment Management, Inc. position in PCVX

VAXCYTE INC · Health Care

T. Rowe Price Investment Management, Inc. reported holding 14,300,004 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$813.7M, representing 0.57% of its reported portfolio and ranking #39 among its reported holdings. T. Rowe Price Investment Management, Inc. has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)14.30M sh
Reported value held$813.67M
Portfolio Weight0.57%
First reportedQ3 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How T. Rowe Price Investment Management, Inc.'s PCVX position evolved

T. Rowe Price Investment Management, Inc. first disclosed a stake in PCVX in Q3 2023 at 1,204,628 shares (US$61.4M). The position peaked in Q3 2026 at 14,300,004 shares, worth US$813.7M. Across 13 filings, T. Rowe Price Investment Management, Inc. increased the stake 10 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 14,300,004 shares valued at US$813.7M — an increase of 2,092,554 shares quarter over quarter.. Notable position changes include a 185% increase in Q1 2024 (shares rose 11% over the following quarter), a 122% increase in Q2 2025 (shares rose 11% over the following quarter), a 39% increase in Q3 2025 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.20M $61.41M New
Q4 2023 1.25M $78.25M Add
Q1 2024 3.55M $242.70M Add
Q2 2024 4.02M $303.75M Add
Q3 2024 4.05M $463.23M Add
Q4 2024 2.86M $234.18M Reduce
Q1 2025 2.70M $102.05M Reduce
Q2 2025 6.00M $195.10M Add
Q3 2025 8.32M $299.52M Add
Q4 2025 11.30M $521.21M Add
Q1 2026 12.13M $704.64M Add
Q2 2026 12.21M $709.62M Add
Q3 2026 14.30M $813.67M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 31 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$1.02B), RA CAPITAL MANAGEMENT, L.P. (US$652.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has T. Rowe Price Investment Management, Inc. held PCVX?

T. Rowe Price Investment Management, Inc. has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is T. Rowe Price Investment Management, Inc.'s current position in PCVX?

As of Q3 2026, T. Rowe Price Investment Management, Inc. holds 14.30M shares of PCVX (VAXCYTE INC), valued at $813.67M, representing 0.57% of its reported portfolio and ranking #39.

Has T. Rowe Price Investment Management, Inc. been buying or selling PCVX?

In the latest 13F filing (Q3 2026), T. Rowe Price Investment Management, Inc. increased its position in PCVX. The position peaked in Q3 2026 at 14.30M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, RA CAPITAL MANAGEMENT, L.P., among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.